By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today said it has received clearance from the US Food and Drug Administration for its Tissue of Origin test for formalin-fixed paraffin embedded tissue.

The Pathwork Tissue of Origin test can now be broadly used on common clinical FFPE tumor specimens from both community and research hospitals, Pathwork Diagnostics said in a statement. The clearance also clears the way for additional FFPE-based cancer tests on its platform, the company added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.